Silence Therapeutics, InteRNA collaborate to develop cancer therapeutics
Silence is currently conducting a Phase I trial with Atu027 in patients with advanced solid cancer. Interim data analysis from this trial showed that Atu027 is safe and
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Olesoxime (TRO19622) is the lead compound of the Trophos’ proprietary cholesterol-oxime compound family of mitochondrial pore modulators. The 24-month randomized, parallel group, double-blind, placebo controlled trial will compare